Marco Gusinu

Marco Gusinu

Auto-generated profile, based on publicly available information

Marco Gusinu

Department of Medical Physics, IRCCS Policlinico San Martino, Genoa, Italy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Medical Dosimetry
Verified
Journal Article
Closed access
MZMichele Zeverino
Michele Zeverino
SAStefano Agostinelli
Stefano Agostinelli
GTGianni Taccini
Gianni Taccini
FCFrancesca Cavagnetto
Francesca Cavagnetto
SGStefania Garelli
Stefania Garelli
RCRenzo CORVO
Renzo CORVO

1 May 2012 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
SAStefano Agostinelli
Stefano Agostinelli
MGMarco Gusinu
Marco Gusinu
FCFrancesca Cavagnetto
Francesca Cavagnetto
SGStefania Garelli
Stefania Garelli
MZMichele Zeverino
Michele Zeverino
GTGianni Taccini
Gianni Taccini

22 November 2010 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
MGMarina Guenzi
Marina Guenzi
Stefano VaggeStefano Vagge
Stefano Vagge
NANgwa Che Azinwi
Ngwa Che Azinwi
ADAlessia D'Alonzo
Alessia D'Alonzo
LBLiliana Belgioia
Liliana Belgioia
RCRenzo CORVO
Renzo CORVO
Background: Radiation therapy after lumpectomy is a standard part of breast conserving therapy for invasive breast carcinoma. The most frequently used schedule worldwide is 60 Gy in 30 fractions in 6 weeks, a time commitment that sporadically may dissuade some otherwise eligible women from undertaking treatment. The purpose and primary endpoint of this perspective study is to evaluate feasibility and short-term late toxicity in a hypofractionated whole breast irradiation schedule. Methods: Between February and October 2008 we treated 65 consecutive patients with operable invasive early-stage breast cancer with a hypofractionated schedule of external beam radiation therapy. All patients were assigned to 39 Gy in 13 fractions in 3 weeks to the whole breast plus a concomitant weekly boost dose to the lumpectomy cavity of 3 Gy in 3 fractions. Results: All the patients had achieved a median follow up of 24 months (range 21-29 months). At the end of treatment 52% presented grade 0 acute toxicity 39% had grade 1 and 9% had grade 2. At 6 months with all the patients assessed there were 34% case of grade 1 subacute toxicity and 6% of grade 2. At 12 months 43% and 3% of patients presented with clinical grade 1 and grade 2 fibrosis respectively and 5% presented grade 1 hyperpigmentation. The remaining patients were free of side effects. At 24 months, with 56 assessed, just 2 patients (3%) showed grade 2 of late fibrosis. Conclusions: The clinical results observed showed a reasonably good feasibility of the accelerated hypofractionated schedule in terms of acute, subacute and short-term late toxicity. This useful 13 fractions with a concomitant boost schedule seems, in selected patients, a biologically acceptable alternative to the traditional 30 days regime.

1 August 2018 in Physica Medica
Verified
Journal Article
Closed access
SAS. Agostinelli
S. Agostinelli
SGS. Garelli
S. Garelli
MGM. Gusinu
M. Gusinu
MZMichele Zeverino
Michele Zeverino
FCF. Cavagnetto
F. Cavagnetto
GTG. Taccini
G. Taccini

1 February 2013
Verified
Journal Article
Closed access
MMMichela Marcenaro
Michela Marcenaro
Stefano VaggeStefano Vagge
Stefano Vagge
LBLiliana Belgioia
Liliana Belgioia
DADario Agnese
Dario Agnese
GLGiorgio Lamanna
Giorgio Lamanna
RCRenzo CORVO
Renzo CORVO

29 October 2019 in In Vivo
Verified
Journal Article
Open access
PDF file
EBElisabetta Bonzano
Elisabetta Bonzano
LBLiliana Belgioia
Liliana Belgioia
GPGiorgia Polizzi
Giorgia Polizzi
GSGuido Siffredi
Guido Siffredi
PFPiero Fregatti
Piero Fregatti
RCRenzo Corvò
Renzo Corvò
Aim: To evaluate once-weekly hypofractionated radiotherapy in elderly patients affected by early breast cancer, reporting acute and late toxicity profiles, and treatment feasibility. Patients and Methods: Fifty patients were treated with a hypofractionated regimen: 28.5±2.5 Gy in five fractions at one fraction weekly. Simultaneous integrated boost (SIB) to the tumor bed in high-risk cases. Inclusion criteria: patients over 70 years old, pT1-2, N0-1a. Acute and late toxicities were assessed based on Radiation Therapy Oncology Group. Results: The median follow-up was 20 months and the median patient age was 79 years. SIB was added for 22 patients (44%). Grade 3-4 acute cutaneous toxicities were not observed; grade 2 toxicity occurred only in four patients (8%). Late subcutaneous tissue toxicity consisted of grade 2 fibrosis in two patients (4%), grade 1 in five (10%) and grade 0 in 41(85%). Conclusion: Limiting fraction numbers with a safer profile may improve the management of breast cancer for the elderly.